Tag Archives: Neumora Therapeutics

Neumora Therapeutics’ head of R&D sells over $490k in company stock, a move that has sent ripples through the pharmaceutical industry. This significant transaction raises questions about the company’s future prospects, the potential impact on investor sentiment, and the broader implications for research and development activities. The sale, which was …

Read More »